Genomic biomarkers of response to nivolumab/ipilimumab (nivo/ipi) and nivolumab (nivo) monotherapy in 108 patients with advanced renal cell carcinoma.
Chung‐Han Lee(Memorial Sloan Kettering Cancer Center), A. Ari Hakimi(Penn State Milton S. Hershey Medical Center), Samuel Murray(Memorial Sloan Kettering Cancer Center), Diego Chowell(Icahn School of Medicine at Mount Sinai), Robert J. Motzer(Memorial Sloan Kettering Cancer Center), Renzo G Di Natale(Memorial Sloan Kettering Cancer Center), Maria I. Carlo(Memorial Sloan Kettering Cancer Center), Vladimir Makarov, Timothy A. Chan(Cleveland Clinic), Darren R. Feldman(Memorial Sloan Kettering Cancer Center), Martin H. Voss(Memorial Sloan Kettering Cancer Center), Almedina Redzematovic(Memorial Sloan Kettering Cancer Center)
Cited by 1
Related Papers
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
|New England Journal of Medicine|2018|4.6k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
|Science|2016|3.1k
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
|Annals of Oncology|2018|2.9k